開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSING IN THE UNITED STATES IN PHASE II CLINICAL TRIAL OF ALK-1 ANTIBODY AND NIVOLUMAB COMBINATION THERAPY FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 2 May 2022, the Company has dosed the first patient in the United States in its multi-regional phase II clinical trial (NCT05178043) of ALK-1 antibody (GT90001) and Nivolumab combination therapy for treatment of advanced hepatocellular carcinoma ("**HCC**") (the "**Phase II Clinical Trial**").

The Phase II Clinical Trial is an open-label, multi-regional study designed to evaluate the efficacy and safety of GT90001 in combination with Nivolumab on patients with advanced HCC who were intolerant of or had progressed after first-line treatment with immune checkpoint inhibitors (ICI) such as Atezolizumab and/or Bevacizumab, or ICI plus tyrosine kinase inhibitor (TKI). The Phase II Clinical Trial will enroll a total of 105 subjects. The proposed dose is 7mg/kg of GT90001 in combination with 240 mg of Nivolumab, infused every two weeks. The primary endpoint is to assess the overall response rate ("**ORR**") as evaluated by an independent review committee according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Previously, preliminary data from the ongoing phase II clinical trial of the combination therapy of GT90001 and Nivolumab on patients with advanced HCC in Taiwan, China was released at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium held in January 2021. The preliminary data showed positive efficacy and good safety results. The ORR was 40 percent. On 9 October 2021, the clinical trial of combination therapy of GT90001 and Nivolumab for the treatment of advanced HCC was approved by the National Medical Products Administration of China. For further details, please refer to the announcements of the Company dated 9 December 2020 and 11 October 2021 respectively.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that ALK-1 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 4 May 2022

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Dr. Yan Wang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*